A Phase I Multicenter, Open-Label, Dose Escalation Trial of R763 Given Orally to Subjects With Solid Tumours.

Trial Profile

A Phase I Multicenter, Open-Label, Dose Escalation Trial of R763 Given Orally to Subjects With Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs R 763 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors EMD Serono
  • Most Recent Events

    • 24 Jan 2012 Additional lead trial investigator (Narmyn Rejeb) identified as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Planned number of patients changed from 108 to 144 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top